ACADIA PHARMACEUTICALS INC

ACAD | Nasdaq Stock Exchange Global Select Market

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Country of Incorporation

United States of America

Incorporation Date

1997-01-16

Business Sector

Pharmaceuticals & Medical Research

Company Address

12830 El Camino Real, Suite 400

Get access to the below data and more business development tools by signing up for the MENA Company Data product.

- Ownership details

- Corporate structure

- Business classification

- Officers & Directors contact details

- Full company contact details

Find out more

Multiply your reach by contributing your content to LSEG

LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.

Find out more